Roche: EMA panel recommends approval of cancer immunotherapy
(CercleFinance.com) - A European Medicines Agency panel on Friday recommended a marketing approval of Roche's Tecentriq, in combination with chemotherapy, as an initial treatment of adults with extensive-stage small cell lung cancer.
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion based on results from a Phase III study which showed that Tecentriq, in combination with chemotherapy, helped people live significantly longer compared with chemotherapy alone.
The median overall survival was 12.3 months, compared to 10.3 months in the chemotherapy arm.
Lung cancer is the leading cause of cancer death worldwide, with SCLC accounting for approximately 15% of all lung cancer cases.
The Roche share is currently up 1.8% in Zurich.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion based on results from a Phase III study which showed that Tecentriq, in combination with chemotherapy, helped people live significantly longer compared with chemotherapy alone.
The median overall survival was 12.3 months, compared to 10.3 months in the chemotherapy arm.
Lung cancer is the leading cause of cancer death worldwide, with SCLC accounting for approximately 15% of all lung cancer cases.
The Roche share is currently up 1.8% in Zurich.
Copyright (c) 2019 CercleFinance.com. All rights reserved.